

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mega Genomics Limited
美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6667)

DATE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Mega Genomics Limited (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Wednesday, 4 February 2026 for the purpose of considering and approving the announcement of the interim results of the Group for the six month ended 30 June 2025 and its publication, the payment of an interim dividend, if any, and transacting any other business.

By order of the Board
Mega Genomics Limited
LIN Lin

Executive Director and Chairperson

Hong Kong, 25 January 2026

As at the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* For identification purpose only